Trial Profile
An Open-Label, Multicenter, Expanded Access Program for Emicizumab in Patients With Hemophilia A With Inhibitors
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Apr 2018
Price :
$35
*
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Expanded access; Therapeutic Use
- Sponsors Genentech
- 26 Mar 2018 Status changed from recruiting to completed.
- 19 May 2017 New trial record